MentionFox
Home › Executive changes › Zevra Therapeutics, Inc.
Leadership changes · ZVRA · SEC Form 8-K, Item 5.02

Leadership changes at Zevra Therapeutics, Inc. (2026)

Before you join, sell to or invest in Zevra Therapeutics, Inc.

MentionFox check on Zevra Therapeutics, Inc.: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/zevra-therapeutics

Check Zevra Therapeutics, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Zevra Therapeutics, Inc.?

Who joined and who left Zevra Therapeutics, Inc. (ZVRA)? 1 appointment reported on 2026-03-09, each cited to the company's own filing.

Justin Renz was named Chief Financial Officer of Zevra Therapeutics, Inc., effective March 9, 2026. As of November 14, 2026, Zevra Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 9, 2026, naming 1 appointment (Form 8-K, March 9, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Woodline Partners LP also filed stake reports on 19 other companies ↓

Sell to companies like Zevra Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
In (appointed)1
Latest filing2026-03-09

Zevra Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-09. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Zevra Therapeutics, Inc. files it.

Also on the record for Zevra Therapeutics, Inc.

DateRecordFigureOur pageSource
November 5, 2026Stake report, Schedule 13G/A, by FMR LLC9.4% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by Woodline Partners LP8.1% of the class5%+ stakesSource
August 6, 2026Stake report, Schedule 13G/A, by FMR LLC8.3% of the class5%+ stakesSource
July 31, 2026Stake report, Schedule 13G, by Vanguard Capital Management5.11% of the class5%+ stakesSource
May 6, 2026Stake report, Schedule 13G, by FMR LLC5.5% of the class5%+ stakesSource
March 27, 2026Stake report, Schedule 13G/A, by The Vanguard Group—5%+ stakesSource
November 14, 2025Stake report, Schedule 13G/A, by Woodline Partners LP6.2% of the class5%+ stakesSource
November 13, 2025Stake report, Schedule 13G/A, by Adage Capital Management, L.P.3.96% of the class5%+ stakesSource

Selling to them or working with them? See who runs Zevra Therapeutics, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on Zevra Therapeutics, Inc. and the records around it.

Zevra Therapeutics, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Zevra Therapeutics, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Zevra Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Zevra Therapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    9 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-03-09InChief Financial Officer2026-03-098-K, 2026-03-09

Who leads Zevra Therapeutics, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Zevra Therapeutics, Inc.?

New leaders reset buying decisions — get the Full Report on Zevra Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Zevra Therapeutics, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Chief Financial Officer at Zevra Therapeutics, Inc., with the record behind each one.

Find candidates like Chief Financial Officer at Zevra Therapeutics, Inc.

Every change, in the filing's words

Filed 2026-03-09 · 8-K

Appointed: Justin Renz, Chief Financial Officer, effective 2026-03-09

On March 4, 2026, the Company appointed Justin Renz as Chief Financial Officer and Treasurer, effective March 9, 2026, and as principal financial officer, effective March 10, 2026.

Also stated in this filing

  • Beginning in 2017, Mr. Renz held various positions of increasing responsibility at Correvio Pharma Corp, a specialty pharmaceutical company, most recently as its President and Chief Financial Officer at the time of its acquisition by Advanz Pharma in May 2020.
  • From 2014 to 2017, Mr. Renz was the Executive Vice President and Chief Financial Officer of Karyopharm Therapeutics, Inc. Prior to that, from 2006 to 2014, Mr. Renz held a variety of financial positions with Zalicus Pharmaceuticals Ltd., a biopharmaceutical company, including most recently as Executive Vice President and Chief Financial Officer at the time of its acquisition by Epirus Biopharmaceuticals, Inc. in 2014.
  • In connection with his employment, Mr. Renz and the Company have entered into an employment agreement (the "Employment Agreement") effective as of March 9, 2026.
  • Under the Employment Agreement, his annualized base salary will be $520,000.
  • Mr. Renz will be eligible to receive an annual performance bonus with a bonus target of 45% of his annual base salary.
  • Mr. Renz will also receive an option to purchase 300,000 shares of the Company's common stock (the "Equity Award") pursuant to and in accordance with the terms and conditions of Company's Amended and Restated 2023 Employment Inducement Award Plan.

Tools for this story

Each opens in a new tab, filled in for Zevra Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/zevra-therapeutics
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Zevra Therapeutics, Inc. names Justin Renz CFO (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/zevra-therapeutics